NCT04858074View on ClinicalTrials.gov

Study to Investigate the Effect of Hypoestes Rosea Powder in Parkinson's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 3, 2022

Primary Completion Date

September 30, 2022

Study Completion Date

December 31, 2022

Conditions
Parkinson Disease
Interventions
DRUG

Hypoestoxide

Its active pharmaceutical ingredient (API) is Hypoestoxide, discovered in 1983, which was recently shown to be active against alpha synuclein and was very effective in modifying disease progression in a transgenic mouse model of PD

Trial Locations (1)

200212

College of Medicine, University of Ibadan, Ibadan

All Listed Sponsors
lead

University of Ibadan

OTHER

NCT04858074 - Study to Investigate the Effect of Hypoestes Rosea Powder in Parkinson's Disease | Biotech Hunter | Biotech Hunter